Roche Launches Ventana BAP1 (SP527) Diagnostic Test
Roche has launched the Ventana BAP1 (SP527) test, an automated tissue diagnostic tool designed to assist in the identification of malignant mesothelioma.
Stocks · News reference
Roper Technologies Analyst Turns Bullish After Q3 Print
JPMorgan upgraded Roper to Neutral rating and raised its target citing organic growth, earnings and software M&A outlook.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
DKSH Acquires Rocephin Antibiotic Brand Rights from Roche
DKSH has acquired the rights to the antibiotic brand Rocephin from Roche.
Goldman Sachs Adjusts Price Target on Roper Technologies to $468 From $410
Goldman Sachs has revised its price target for Roper Technologies, increasing it to $468 from the previous $410.
Argus Adjusts Price Target on Roper Technologies to $480
Argus has increased its price target for Roper Technologies, moving it from $450 to $480.